Bausch Health Boosts Ad Spending For Expanding Supplement Lineup
This article was originally published in The Rose Sheet
Executive Summary
Canadian firm, recently renamed from Valeant Pharmaceuticals International, includes launches of Ocuvite Blue Light and PreserVision AREDS 2 Formula Chewable vitamins among its reasons for increasing its consumer health advertising spending. Q2 revenues for its consumer health segment were up 5% organically to $369m.
You may also be interested in...
Health, Beauty And Wellness News: Ocuvite Blue Light, NIH Herbal App
Nutraceutical Corp. refutes California lead claim; CRN Conference, Workshop registration open; GMA appoints Freeman to helm; Ocuvite Blue Light for digital protection; and NIH app for herbals.
Debt-laden Valeant Sells Its Assets, More Divestments Likely
Troubled Valeant has started the new year by announcing the sale of some $2.1bn in assets to get funds to hone down its operations and to start easing its debt burden amid allegations of unethical practices.
Former Valeant, Philidor Execs Charged With Elaborate Kickback Scheme
Specialty mail-order pharmacy Philidor was held up as an example of how Valeant was bilking patients when the usually close arrangement initially came to light; now it seems that Valeant itself was allegedly getting bilked.